Risankizumab Therapy for Moderate-to-Severe Psoriasis-A Multi-Center, Long-Term, Real-Life Study from Poland
Michał Adamczyk,Joanna Bartosińska,Dorota Raczkiewicz,Kinga Adamska,Zygmunt Adamski,Maria Czubek,Beata Kręcisz,Elżbieta Kłujszo,Aleksandra Lesiak,Joanna Narbutt,Marcin Noweta,Agnieszka Owczarczyk-Saczonek,Witold Owczarek,Adam Reich,Dominik Samotij,Aleksandra Siekierko,Justyna Szczęch,Irena Walecka,Piotr Ciechanowicz,Anna Woźniacka,Agata Liszewska,Dorota Krasowska
DOI: https://doi.org/10.3390/jcm12041675
2023-02-20
Abstract:The present multi-center, long-term, real-life study made an attempt to assess the efficacy of risankizumab in the treatment of moderate-to-severe plaque psoriasis. The study comprised 185 patients from 10 Polish dermatologic departments undergoing risankizumab treatment. The disease severity was measured using the Psoriasis Area and Severity Index (PASI) before the start of the risankizumab treatment and next at the defined timepoints, i.e., 4, 16, 28, 40, 52 and 96 weeks of treatment. The percentage of patients achieving PASI90 and PASI100 responses as well as the PASI percentage decrease at the defined timepoints were calculated, and correlations with clinical characteristics and therapeutic effect were analyzed. The number of patients evaluated at the defined timepoints was: 136, 145, 100, 93, 62, and 22 at 4, 16, 28, 40, 52 and 96 weeks of treatment, respectively. At 4, 16, 28, 40, 52 and 96 weeks, the PASI90 response was achieved in 13.2%, 81.4%, 87.0%, 86.0%, 88.7% and 81.8% of patients, whereas the PASI100 response was achieved in 2.9%, 53.1%, 67.0%, 68.8%, 71.0% and 68.2% of patients, respectively. Our study revealed a significant negative correlation between a decrease in the PASI and the presence of psoriatic arthritis as well as the patient's age and duration of psoriasis at several timepoints throughout the observation period.